Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: ^NBI).
SAN DIEGO, /PRNewswire/ -- Mirati Therapeutics Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: ^NBI). The Company's addition to the Index will become effective prior to market open on Monday, December 24, 2018. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). Companies in the NBI must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria. The index is evaluated semi-annually in May and November and serves as the basis for the iShares NASDAQ Biotechnology Index Fund (Nasdaq: IBB). For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit https://indexes.nasdaqomx.com/Index/Overview/NBI. About Mirati Therapeutics
SOURCE Mirati Therapeutics, Inc. |
||
Company Codes: NASDAQ-SMALL:MRTX, NASDAQ-NMS:IBB |